InsightRX, a San Francisco, CA-based software company leveraging quantitative pharmacology and artificial intelligence (AI), received a Growth financing form CIBC Innovation Banking.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and development efforts.
Led by CEO Sirj Goswami, InsightRX applies patient-specific data and quantitative models to tailor dosing for complex treatments, including antibiotics, chemotherapeutic agents, and immunosuppressants. The company also employs AI to empower data scientists in analyzing clinical trial data, aiding in trial design, understanding dose-exposure-response relationships, and refining dosing strategies for regulatory submissions.
Its platform provides an individualized understanding of a patient’s response to treatment, enabling medical professionals to bring new drugs to market efficiently, improve treatment effectiveness, and provide direct benefits to patients.
Commenting on the news, Sirj Goswami said: “We are proud that InsightRX is leading the transition from the traditional ‘one-size-fits-all’ approach in drug dosing to a more individualized treatment paradigm that considers the unique characteristics of patient subgroups and the specific needs of each patient. This shift is not just pivotal for patient care but also for the introduction of new drugs to the market. To help us achieve our strategic vision of transforming patient care, we worked with CIBC for the necessary financing to accelerate our growth. CIBC showed intellectual curiosity about the intricacies of our business and were thoughtful in their approach.”
FinSMEs
25/02/2024